Infliximab for the Treatment of Refractory Noninfectious Uveitis: A Study of 88 Patients with Long-term Follow-up – Corrected Proof
Objective: To establish the safety and efficacy of infliximab for the treatment of refractory noninfectious uveitis.Design: Retrospective, interventional, noncomparative cohort study.Participants: Eighty-eight patients from a single-center private practice.Methods: Patients with chronic, recalcitrant uveitis treated with infliximab (Remicade; Janssen Biotech, Inc., Titusville, NJ) were identified through an electronic medical record database. All charts were reviewed for sex, diagnosis, location of inflammation, presence of vasculitis, prior immunomodulatory treatments, duration of infliximab treatment, dose received, secondary side effects, and other medications continued while receiving treatment with infliximab.Main Outcome Measures: The primary outcome measures were the rate of remission, time to remission, relapse rate, (Read more...)